ADAR1 Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

ADAR1 Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-48,044	Closed	-$6.34M	–	246
2025 Q1	$6.34M	Buy	+48,044	New	+$5.99M	1.18%	21
2024 Q4	–	Sell	-13,400	Closed	-$980K	–	320
2024 Q3	$980K	Buy	+13,400	New	+$1.01M	0.16%	79

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

ADAR1 Capital Management's ITCI Position: Q2 2025 in Review

ADAR1 Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 48,044 shares — an estimated $6.34M sold.

ADAR1 Capital Management first reported a position in ITCI in Q3 2024 and held it in 2 quarters. The position peaked at $6.34M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

ADAR1 Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
ADAR1 Capital Management sold 48,044 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $6.34M.
ADAR1 Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 2 quarters.
ADAR1 Capital Management's Intra-Cellular Therapies Inc. position peaked at $6.34M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.